Luxturna (voretigene neparvovec-rzyl) / The Children’s Hospital of Philadelphia, Novartis, Roche  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Luxturna (voretigene neparvovec-rzyl) / Novartis, Roche
NCT00999609 / 2016-002109-20: Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

Checkmark AAPOS 2018
Apr 2018 - Apr 2018: AAPOS 2018
Checkmark For Leber Congenital Amaurosis
Jul 2017 - Jul 2017: For Leber Congenital Amaurosis
Checkmark
More
Active, not recruiting
3
31
US
AAV2-hRPE65v2,voretigene neparvovec-rzyl, AAV2-hRPE65v2, voretigene neparvovec-rzyl, gene therapy vector
Spark Therapeutics, Inc., Children's Hospital of Philadelphia, University of Iowa
Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis
07/15
07/29
CLTW888A11301, NCT04516369: Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Active, not recruiting
3
4
Japan
voretigene neparvovec
Novartis Pharmaceuticals
Biallelic RPE65 Mutation-associated Retinal Dystrophy
04/22
05/26

Download Options